The Top 5 Biosimilars Articles for the Week of December 2
The Center for Biosimilars® recaps the top stories for the week of December 2, 2019.
Transcript
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 2, 2019.
Number 5: Writing in a perspective article in The New England Journal of Medicine, a noted critic of high pharmaceutical prices proposed targets for drug price negotiation.
Number 4: A recent study reports that pricing decisions for multiple sclerosis drugs are not the result of needing to recoup specific research and development costs.
Number 3: The FDA released draft guidance for industry on clinical immunogenicity considerations for biosimilar insulins and interchangeable insulins.
Number 2: The European Commission has released a new report that highlights the role that biosimilars and generics will have in the well-being of European healthcare systems in the years ahead.
Number 1: Mylan and Biocon announced that their biosimilar trastuzumab, Ogivri, has become commercially available in the United States.
Finally, last week, our e-newsletter asked which group you think has the greatest responsibility to educate patients about biosimilars and biologics.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
